The present invention relates to a pharmaceutical formulation of solid dosageforms comprising a therapeuticallyeffective amount of a pyrrolidone anticonvulsant agent, and in particularLevetiracetam or a pharmaceutical acceptable salt or derivativethereof, in combination with an effective diluent, such as Dibasic CalciumPhosphate, and additional pharmaceutical excipients,and a process for the preparation thereof by wet granulation.